Researchers at the University of Glasgow have developed the first bioengineered human bone-marrow model to test CAR T-cell therapies for acute myeloid leukaemia, offering a more accurate, non-animal testing platform.
Dr Jeanine Houwing-Duistermaat (statistics) and Dr Gastone Castellani (biophysics) from the University of Bologna, Italy, organised innovative interdisciplinary training in multi-omics research within the IMforFUTURE project, which focused on communication between wet and dry lab.
At the University of Freiburg, scientists have created artificial muscles from natural proteins - less Dr Frankenstein, more future potential for reconstructive medicine or soft robotics.
Dr Glass, Director of the Fogarty International Center, and Director at the NIH, explores the relationship between NIH and the health research community
Targeted neuromodulation may be a future method to help those with severe, untreatable depression - traditionally, this is used to correct misfiring brain circuits in people with epilepsy or Parkinson's.
Scientists at the University of Tsukuba reveal that brain refreshing takes place during the dreaming phase of sleep, aka rapid eye movement (REM) sleep.
L. Maximilian Buja, MD, Professor of Pathology and Laboratory Medicine at McGovern Medical School, The University of Texas Health Science Center at Houston, turns the spotlight onto medical education both past and present.
Mutlu Özcan, Prof. Dr Dr h.c., PhD from the University of Zürich, highlights Reconstructive Dentistry through new biomaterials and technologies, including the associated changes and challenges.
Professor Darren Griffin reflects on how patients in fertility clinics should interpret the scientific evidence base when even the experts can’t seem to agree.
Michael Morrison, Senior Researcher in Social Science at the University of Oxford, illustrates the importance of emerging biomedical innovations in the UK.
The research team believe that some people have a genetic predisposition that increases likelihood of severe COVID, which may be crucial to understanding how mutations could change outcomes.
The Pfizer and BioNTech vaccine appears to be significantly less efficient against the South African mutation, but can still stop hosts from experiencing severe COVID and dying from the virus.
